Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $12.71, for a total transaction of $699,050.00. Following the completion of the transaction, the chief executive officer now owns 221,017 shares in the company, valued at $2,809,126.07. This represents a 19.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Monday, April 21st, Saurabh Saha sold 14,656 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.29, for a total transaction of $180,122.24.
• On Thursday, March 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.69, for a total transaction of $917,950.00.
• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00.

Centessa Pharmaceuticals Price Performance

CNTA opened at $13.20 on Wednesday. The company has a 50-day moving average of $13.31 and a 200-day moving average of $15.54. The company has a market capitalization of $1.76 billion, a P/E ratio of -8.63 and a beta of 1.53. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.15. Equities analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Analyst Ratings Changes

CNTA has been the topic of a number of recent analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a “buy” rating and a $30.00 price objective on the stock. Guggenheim reissued a “buy” rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an “overweight” rating and a $38.00 target price for the company. Finally, Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 target price for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $27.00.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $31,000. Caitong International Asset Management Co. Ltd raised its stake in Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after acquiring an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new stake in Centessa Pharmaceuticals during the first quarter worth about $47,000. Barclays PLC raised its stake in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Centessa Pharmaceuticals during the first quarter worth about $147,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.